Serum and Salivary Cancer Antigen 125 in Non-Hodgkin Lymphoma Patients Received Chemotherapy

Aim of study: to measure salivary flow rate, serum and salivary cancer antigen 125 levels in non-Hodgkin's lymphoma patients in comparison with healthy looking subjects. Sixty (60) subjects were enrolled in this study, they were divided into two groups: Patients group comprised of 30 non-Hodgkin's lymphoma patients; Control group comprised of 30 healthy looking subjects. Saliva collected was measured and levels of serum and salivary cancer antigen 125 were measured at three times intervals; first before received chemotherapy, after received 3 cycles of chemotherapy and after one month post-chemotherapy using Enzyme-linked Immunosorbent Assay (Elisa). Present results showed that the mean salivary flow rate in non-Hodgkin's lymphoma patients was significantly decrease than in healthy looking subjects, and mean salivary flow rate in non-Hodgkin's lymphoma patients was highest significant in patient before chemotherapy and lower after received 3 cycles chemotherapy. The result showed also mean serum and salivary cancer antigen 125 in non-Hodgkin's lymphoma patients was significantly higher than control group. The mean serum and salivary cancer antigen 125 in non-Hodgkin's lymphoma patients was highest significant in patient before chemotherapy and lower at one month post chemotherapy using ANOVA test.